Diversity evolution of hepatitis B virus quasispecies during the primary stage: correlation with longterm Entecavir antiviral efficacy
10.3760/cma.j.issn.1003-9279.2014.01.012
- VernacularTitle:恩替卡韦初治患者早期乙型肝炎病毒准种多样性变化与疗效关系的研究
- Author:
Fei LIU
1
;
Jing WU
;
Xiaoxiao HUANG
;
Shourong LIU
Author Information
1. 浙江中医药大学第二临床医学院
- Keywords:
Hepatitis B,chronic;
Entecavir
- From:
Chinese Journal of Experimental and Clinical Virology
2014;28(1):35-37
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the diversity evolution of hepatitis B virus(HBV) quasispecies during the long-term entecavir therapy and its impact on the virological reponse.Methods Sixty-four chronic hepatitis B patients were received Entecavir therapy for the first time.Serum samples were collected at six different time points during Entecavir therapy (0,4,12,24,36,48weeks,respectively).Twenty-two patients could be detected HBV DNA at week 4,which were divided into two groups according to the therapeutic effect at week 12:complete response group (ll cases) and partial response group (11 cases).The sequence of HBV RT region was amplified by polymerase chain reaction(PCR) and cloned into T-vector for these serum samples at baseline and week 4.Twenty to thirty clones per sample were selected,sequenced and analyzed.Results Despite comparable at baseline,the diversity change of HBV quasispecies in complete responders were statistically higher than those of partial reponders in week 4 (P ＜ 0.05).Conclusion The HBV quasispecies changed during the primary stage of Entecavir treament.And the heterogeneity of HBV quasispecies during the first 4 weeks was significant association with the long term therapeutic outcome of Entecavir.
